Daniel S. Lorrain - 23 Dec 2025 Form 4 Insider Report for Contineum Therapeutics, Inc. (CTNM)

Role
Chief Scientific Officer
Signature
/s/ Peter Slover, Attorney-in-Fact
Issuer symbol
CTNM
Transactions as of
23 Dec 2025
Net transactions value
-$51,009
Form type
4
Filing time
30 Dec 2025, 16:10:34 UTC
Previous filing
31 Jan 2025
Next filing
06 Jan 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Lorrain Daniel S. Chief Scientific Officer 3565 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO /s/ Peter Slover, Attorney-in-Fact 30 Dec 2025 0001861550

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CTNM Class A Common Stock Sale $51,009 -4,170 -2.5% $12.23 164,392 23 Dec 2025 Direct F1, F2
holding CTNM Class A Common Stock 6,842 23 Dec 2025 By Spouse F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.00 to $12.38, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
F3 Includes 1,364 shares purchased through Issuer's Employee Stock Purchase Plan on May 15, 2025, and 1,580 shares purchased through Issuer's Employee Stock Purchase Plan on November 14, 2025.